Home LiteratureArticle Details
PMID: 19731239 Published · ppublish English Journal Article

Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.

Hepatology (Baltimore, Md.) ·Vol. 50 ·No. 5 ·2009-11-00 ·Pages 1475-83

N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M, Seror O

Abstract

For the treatment of small hepatocellular carcinoma (HCC), radiofrequency ablation (RFA) is in some centers considered a first-line therapeutic option. However, such a strategy is still under debate with regard to tumor and patient characteristics. In this single-center study we assessed the 5-year survival and prognosis factors in 235 consecutive patients with cirrhosis (Child-Pugh A/B: 205/30) who received RFA as first-line treatment for up to three HCC <or=5 cm (307 tumors; mean diameter: 29 +/- 10 mm; 53 multinodular forms). Among these patients, 67 satisfied the criteria for resection according to the Barcelona Clinic Liver Cancer. Complete ablation was obtained in 222 patients (94%). Overall, 337 RFA sessions were performed including iterative RFA for recurrence. Major complications occurred in three patients (0.9%), including one treatment-related death. After 27 +/- 20 months of mean follow-up, local or distant, or both, tumor recurrence occurred in 16, 88, and 11 patients, respectively. Twenty-nine patients underwent transplantation and were removed from the study at this point. Overall 5-year, recurrence-free, and tumor-free (including results of iterative RFA) survival rates were, respectively, 40%, 17%, and 32%. The overall 5-year survival rate was 76% for operable patients. Factors associated with overall survival were prothrombin activity (hazard ratio [HR] = 0.97, 0.96-0.98; P < 0.0001) and serum levels of alpha-fetoprotein (AFP) (HR = 1.02, 1.02-1.02; P < 0.0001), and factors associated with tumor recurrence were multinodular forms (HR = 2.34; 1.52-3.6; P = 0.0001) and serum AFP levels (HR = 1.015, 1.014-1.016; P = 0.015). Tumor size was associated with local recurrence but not with overall and tumor-free survival. RFA is a safe and effective first-line treatment of HCC up to 5 cm in diameter, especially for patients with a single tumor, a low serum AFP level, and well-preserved liver function.

MeSH Terms
Adult Aged Aged, 80 and over Carcinoma, Hepatocellular/diagnosis,ethnology,surgery Catheter Ablation Cohort Studies Female Follow-Up Studies Humans Kaplan-Meier Estimate Liver/pathology,surgery Liver Cirrhosis Liver Neoplasms/diagnosis,ethnology,surgery Male Middle Aged Prognosis Retrospective Studies Spain Survival Rate Treatment Outcome
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
N'Kontchou Gisèle
Department of Hepatogastroenterology, Hôpital Jean Verdier (Assistance Publique-Hôpitaux de Paris), Bondy, France.
Mahamoudi Amel
Aout Mounir
Ganne-Carrié Nathalie
Grando Véronique
Coderc Emmanuelle
Vicaut Eric
Trinchet Jean Claude
Sellier Nicolas
Beaugrand Michel
Seror Olivier
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
1527-3350
Published
2009-11-00
Pages
1475-83
Language
English
Region
United States
NLM ID
8302946
Subset
IM
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com